Public health, innovation, intellectual property and trade

Trends in the pharmaceutical industry and potential impact on future innovation and access to medicines

A panel discussion with

  • Brian Tempest, former CEO of Ranbaxy
  • Ellen 't Hoen, Medicines Patent Pool Foundation
  • Andrew Jenner, IFPMA
  • Peter Beyer, WHO

Moderated by Zafar Mirza, WHO

Wednesday, 25 April 2012, 14.00 to 16.00
Salle Kofi Annan (UNAIDS building)

The pharmaceutical industry is changing the way it develops medicines and business initiatives, faced with a diminishing product pipelines, emerging and dynamic global markets and increasing demand for access to medicines for both infectious and chronic conditions. Research-based pharmaceutical giants are no longer the only parties innovating and they are increasingly seeking partnerships with generics manufacturers in developing countries. As companies develop innovative models for research, the traditional system of intellectual property protection will have to accommodate more open models of drug development, compound sharing, and patent pooling. A recent compulsory license issued by the Government of India for an oncology medicine may indicate the beginning of a yet another trend. The WHO Department of Public Health, Innovation and Intellectual Property will be holding a panel discussion with representatives from industry and cutting edge initiatives like the Medicines Patent Pool Foundation to discuss what the future may hold for the pharmaceutical industry, intellectual property protection, and most importantly, for public health and access to medicines.

Share